Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement

March 11, 2020

View Press Release Corporate presentation Contact us
Previous